Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells

Oncogene volume 19, pages 4640–4646 (2000)Cite this article

Abstract

We previously reported that all-trans retinoic acid (ATRA) and granulocyte-macrophage colony-stimulating factor (GM–CSF) synergistically induced granulocytic differentiation in human myeloblastic leukemia ML-1 cells. The combination of these agents also suppressed DNA-synthesis. In the present study, we investigated the suppression of cyclin dependent kinase (CDK) activities resulting in G1 arrest in differentiated ML-1 cells. We show that treatment of ML-1 cells with ATRA plus GM-CSF results in G1 arrest and suppression of CDK activities. Protein levels of the G1 CDKs were essentially unchanged during this time. However, we observed an increase in CDK2-bound p27 and CDK4-bound p18, and a decrease in CDK6-bound cyclin D3. These results suggest that complex regulation of CDKs play a key role in G1 arrest of ML-1 after treatment with ATRA and GM–CSF. We also showed that an increase in CDK2-bound p27 and CDK4-bound p18 are caused by treatment with ATRA and a decrease in CDK6-bound cyclin D3 is induced synergistically by treatment with both reagents. Furthermore, we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in p27 binding to CDK2 is due to a novel mechanism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Asiedu C, Biggs J and Kraft AS. . 1997 Blood 90: 3430–3437.

  • Chan FKM, Zhang J, Cheng L, Shapiro DN and Winoto A. . 1995 Mol. Cell. Biol. 15: 2682–2688.

  • Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ. . 1999 EMBO J. 18: 1571–1583.

  • Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI. . 1994 Cell 76: 1013–1023.

  • El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.

  • Fang F and Newport JW. . 1991 Cell 66: 731–742.

  • Franklin DS and Xiong Y. . 1996 Mol. Biol. Cell 7: 1587–1599.

  • Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG and Xiong Y. . 1994 Gene Dev. 8: 2939–2952.

  • Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D and Lassar AB. . 1995 Science 267: 1018–1021.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ. . 1993 Cell 75: 805–816.

  • Hirai H, Roussel MF, Kato J-Y, Ashmun RA and Sherr CJ. . 1995 Mol. Cell. Biol. 15: 2672–2681.

  • Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts JM. . 1992 Science 257: 1689–1694.

  • Langenfeld J, Kiyokawa H, Sekula D, Boyle J and Dmitrovsky E. . 1997 Proc. Natl. Acad. Sci. USA 94: 12070–12074.

  • Lee M-H, Reynisdóttir I and Massagué J. . 1995 Genes Dev. 9: 639–649.

  • Liu M, Lee M-H, Cohen M, Bommakanti M and Freedman LP. . 1996 Gene Dev. 10: 142–153.

  • Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF and Sherr CJ. . 1992 Cell 71: 323–334.

  • Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato J-Y. . 1994 Mol. Cell. Biol. 14: 2066–2076.

  • Matsuo T and Thiele CJ. . 1998 Oncogene 16: 3337–3343.

  • Morse L, Chen D, Franklin D, Xiong Y and Chen-Kiang S. . 1997 Immunity 6: 47–56.

  • Müller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W and Eilers M. . 1997 Oncogene 15: 2561–2576.

  • Naderi S and Blomhoff K. . 1999 Blood 94: 1348–1358.

  • Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR. . 1994 Exp. Cell Res. 211: 90–98.

  • Norbury C and Nurse P. . 1992 Annu. Rev. Biochem. 61: 441–470.

  • Oka Y and Takeda K. . 1997 Anticancer Res. 17: 1951–1956.

  • Orend G, Hunter T and Ruoslahti E. . 1998 Oncogene 16: 2575–2583.

  • Pardee AB. . 1989 Science 246: 603–608.

  • Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massagué J. . 1994a Cell 78: 59–66.

  • Polyak K, Kato J-Y, Solomon MJ, Sherr CJ, Massagué J, Roberts JM and Koff A. . 1994b Genes Dev. 8: 9–22.

  • Rao S, Lowe M, Herliczek TW and Keyomarsi K. . 1998 Oncogene 17: 2393–2402.

  • Reynisdóttir I, Polyak K, Iavarone A and Massagué J. . 1995 Genes Dev. 9: 1831–1845.

  • Reynisdóttir I and Massagué J. . 1997 Genes Dev. 11: 492–503.

  • Rosenblatt J, Gu Y and Morgan DO. . 1992 Proc. Natl. Acad. Sci. USA 89: 2824–2828.

  • Saito Y, Hatta H, Mano Y, Taira N, Shimizu T and Takeda K. . 1999 Anticancer Res. 19: 1069–1076.

  • Schwaller J, Pabst TH, Koeffler HP, Niklaus G, Loetscher P, Fey MF and Tobler A. . 1997 Leukemia 11: 54–63.

  • Serrano M, Hannon GJ and Beach D. . 1993 Nature 366: 704–707.

  • Sherr CJ and Roberts JM. . 1995 Genes Dev. 9: 1149–1163.

  • Sherr CJ and Roberts JM. . 1999 Genes Dev. 13: 1501–1512.

  • Shimizu T, Oka Y, Awai N and Takeda K. . 1999 Leukemia Res. 23: 901–907.

  • Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M and Loda M. . 1998 Cancer Res. 58: 1730–1735.

  • Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ and Dmitrovsky E. . 1999 J. Biol. Chem. 274: 22013–22018.

  • Sueoka N, Lee H-Y, Walsh GL, Hong WK and Kurie JM. . 1999 Cancer Res. 59: 3838–3844.

  • Takeda K, Minowada J and Bloch A. . 1982 Cancer Res. 42: 5152–5158.

  • Takeda K, Iwamoto S, Sugimoto H, Takuma T, Kawatani N, Noda M, Masaki A, Morise H, Arimura H and Konno K. . 1986 Nature 323: 338–340.

  • Takei M, Takeda K and Konno K. . 1984 Biochem. Biophys. Res. Commun. 124: 100–105.

  • Toyoshima H and Hunter T. . 1994 Cell 78: 67–74.

  • Wang QM, Jones JB and Studzinski GP. . 1996 Cancer Res. 56: 264–267.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. . 1993 Nature 366: 701–704.

Download references

Author information

Authors and Affiliations

  1. Department of Hygiene-chemistry, Faculty of Pharmaceutical Sciences, Science University of Tokyo, 12 Ichigaya Funagawara-Machi, Shinjuku-ku, Tokyo, 162-0826, Japan

    Takahisa Shimizu, Nao Awai & Ken Takeda

Authors
  1. Takahisa Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nao Awai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimizu, T., Awai, N. & Takeda, K. Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells. Oncogene 19, 4640–4646 (2000). https://doi.org/10.1038/sj.onc.1203821

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203821

Keywords

This article is cited by

Search

Advanced search

Quick links